Business
New Data To Be Presented at 2023 ASCO GU Suggest Decipher GRID-Derived Gene Expression Signature Can Help Personalize Prostate Cancer Treatment
Additional findings from G-MINOR trial reinforce clinical utility of Veracyte’s Decipher Prostate Genomic Classifier SOUTH SAN FRANCISCO, Calif.--(BUSINESS
About this update from Veracyte, Inc.
[{"type":"text","content":"\nAdditional findings from G-MINOR trial reinforce clinical utility of Veracyte’s Decipher Prostate Genomic Classifier\n\n SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--\nVeracyte, Inc. (Nasdaq: VCYT) announced new data being presented this week at the 2023 American Society of Clinical Oncology Genitourinary (ASCO GU) Symposium which demonstrate that a gene expression signature derived from the company’s proprietary Decipher Genomics Resource for Intelligent Discovery (GRID) database may help physicians further personalize treatment for men with prostate cancer, based on their tumor’s molecular subtype. Additional data being presented at the meeting, taking place in San Francisco and online, February 16-18, reinforce the clinical utility of the company’s Decipher Prostate Genomic Classifier.\n\nIn the first study (Abstract #241; Poster #J6), researchers analyzed data from Veracyte’s Decipher GRID database and found that classifying prostate cancer tumors by their molecular subtype could potentially inform their response to treatment. The researchers evaluated 1,015 men with either localized or metastatic hormone-sensitive prostate cancer (mHSPC) using a Decipher GRID-derived, 215-gene expression signature that was previously shown to classify prostate cancer into four molecular subtypes: luminal differentiated, luminal proliferating, basal immune, and basal neuroendocrine-like.\n\nThe findings demonstrated that, after radical prostatectomy, men with luminal differentiated tumors had the most favorable prognosis and those with basal immune tumors derived the greatest metastasis-free survival benefit from postoperative radiotherapy, while those with other subtypes did not see the same benefit. Additionally, in men with metastatic disease, those with luminal proliferating tumors derived the greatest survival benefit from the addition of docetaxel to androgen deprivation therapy.\n\n“These findings demonstrate that our Decipher GRID database can provide researchers with new insights that may help physicians further apply a precision medicine approach to treatment of their prostate cancer patients,” said Elai Davicioni, Ph.D., Veracyte’s medical director for Urology. “This and the multiple, additional Decipher-focused abstracts being presented at ASCO GU reinforce our commitment to research that aims to help physicians provide their ...